IMMX · Immix Biopharma Inc. Common Stock
View on chartInsiders & Stakes
| Rachman Ilya M CEO and Chairman | ▲ Buy | Open Market | 1,141,683 Shares held | 12/10/2025 | View profile |
| Torchilin Vladimir P Scientific Co-Founder | ▲ Buy | Open Market | 905,200 Shares held | 12/20/2021 | View profile |
| Senn Sean 10% Owner | ▼ Sell | Open Market | 899,800 Shares held | 7/14/2022 | View profile |
| Hsu Jason Director | ▲ Buy | Grant | 899,250 Shares held | 5/22/2026 | View profile |
| CHANG NANCY T Director | ▲ Buy | Grant | 428,190 Shares held | 5/22/2026 | View profile |
| Morris Gabriel S Chief Financial Officer | ▲ Buy | Open Market | 291,429 Shares held | 12/10/2025 | View profile |
| Adams Helen C. Director | ▲ Buy | Grant | 181,004 Shares held | 5/22/2026 | View profile |
| Magda Marquet Director | ▲ Buy | Grant | 52,342 Shares held | 5/22/2026 | View profile |
| BUCHAN MELISSA JANE Director | ▲ Buy | Grant | 28,705 Shares held | 5/22/2026 | View profile |
| Ng Carey Director | ▲ Buy | Grant | 26,250 Shares held | 5/22/2026 | View profile |
| Yekaterina Chudnovsky Director | ▲ Buy | Grant | 6,250 Shares held | 5/22/2026 | View profile |
Transaction History
| Adams Helen C. | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 |
| Ng Carey | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 |
| Magda Marquet | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 |
| CHANG NANCY T | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 |
| Yekaterina Chudnovsky | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 |
| Hsu Jason | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 |
| BUCHAN MELISSA JANE | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 |
| Rachman Ilya M | ▲ Buy | Open Market | 746 | $5K | 12/10/2025 |
| Morris Gabriel S | ▲ Buy | Open Market | 770 | $5K | 12/10/2025 |
| Morris Gabriel S | ▼ Sell | Other | 156,000 | $125K | 12/8/2025 |
| Rachman Ilya M | ▲ Buy | Open Market | 2,500 | $5K | 9/17/2025 |
| Morris Gabriel S | ▲ Buy | Open Market | 2,600 | $5K | 9/16/2025 |
| Rachman Ilya M | ▲ Buy | Open Market | 2,178 | $5K | 6/18/2025 |
| Morris Gabriel S | ▲ Buy | Open Market | 2,225 | $5K | 6/18/2025 |
| Hsu Jason | ▲ Buy | Open Market | 40,000 | $88K | 12/23/2024 |
| Hsu Jason | ▲ Buy | Open Market | 7,700 | $17K | 12/20/2024 |
| Hsu Jason | ▲ Buy | Open Market | 8,100 | $18K | 8/22/2024 |
| Hsu Jason | ▲ Buy | Open Market | 15,000 | $33K | 8/21/2024 |
| Ng Carey | ▲ Buy | Open Market | 10,000 | $19K | 8/16/2024 |
| Hsu Jason | ▲ Buy | Open Market | 6,000 | $13K | 7/24/2024 |
| Hsu Jason | ▲ Buy | Open Market | 3,200 | $7K | 7/18/2024 |
| Morris Gabriel S | ▲ Buy | Open Market | 2,500 | $5K | 6/7/2024 |
| Rachman Ilya M | ▲ Buy | Open Market | 2,600 | $6K | 6/7/2024 |
| Morris Gabriel S | ▲ Buy | Open Market | 3,300 | $6K | 6/4/2024 |
| Rachman Ilya M | ▲ Buy | Open Market | 3,300 | $6K | 6/4/2024 |
| Adams Helen C. | ▲ Buy | Grant | 74,241 | — | 5/20/2024 |
| Rachman Ilya M | ▲ Buy | Grant | 218,359 | — | 5/20/2024 |
| BUCHAN MELISSA JANE | ▲ Buy | Grant | 1,127 | — | 5/20/2024 |
| Magda Marquet | ▲ Buy | Grant | 21,155 | — | 5/20/2024 |
| Morris Gabriel S | ▲ Buy | Grant | 194,218 | — | 5/20/2024 |
| Morris Gabriel S | ▲ Buy | Grant | 24,141 | — | 5/20/2024 |
| Morris Gabriel S | ▲ Buy | Grant | 24,141 | — | 5/20/2024 |
| Adams Helen C. | ▲ Buy | Grant | 87,740 | $0 | 5/15/2024 |
| BUCHAN MELISSA JANE | ▲ Buy | Grant | 1,332 | $0 | 5/15/2024 |
| Magda Marquet | ▲ Buy | Grant | 25,002 | $0 | 5/15/2024 |
| Morris Gabriel S | ▲ Buy | Open Market | 4,500 | $10K | 5/14/2024 |
| Rachman Ilya M | ▲ Buy | Open Market | 4,300 | $10K | 5/14/2024 |
| Hsu Jason | ▲ Buy | Open Market | 31,000 | $145K | 12/11/2023 |
| Hsu Jason | ▲ Buy | Open Market | 25,000 | $122K | 12/8/2023 |
| Hsu Jason | ▲ Buy | Open Market | 7,000 | $17K | 9/15/2023 |
| Hsu Jason | ▲ Buy | Open Market | 10,000 | $26K | 9/14/2023 |
| Ng Carey | ▲ Buy | Open Market | 10,000 | $26K | 9/14/2023 |
| Hsu Jason | ▲ Buy | Open Market | 30,000 | $85K | 9/12/2023 |
| Adams Helen C. | ▲ Buy | Open Market | 13,000 | $38K | 9/12/2023 |
| Hsu Jason | ▲ Buy | Open Market | 25,000 | $72K | 9/11/2023 |
| Hsu Jason | ▲ Buy | Open Market | 10,000 | $25K | 9/8/2023 |
| BUCHAN MELISSA JANE | ▲ Buy | Open Market | 20,000 | $49K | 9/7/2023 |
| Magda Marquet | ▲ Buy | Open Market | 9,000 | $22K | 9/6/2023 |
| Magda Marquet | ▲ Buy | Open Market | 10,000 | $25K | 9/5/2023 |
| Magda Marquet | ▲ Buy | Open Market | 1,000 | $2K | 8/31/2023 |
| Rachman Ilya M | ▲ Buy | Open Market | 4,050 | $4K | 11/14/2022 |
| Rachman Ilya M | ▲ Buy | Open Market | 1,000 | $950 | 11/14/2022 |
| Rachman Ilya M | ▲ Buy | Open Market | 150 | $149 | 11/14/2022 |
| Morris Gabriel S | ▲ Buy | Open Market | 5,200 | $5K | 11/14/2022 |
| Senn Sean | ▼ Sell | Open Market | 200 | $550 | 7/14/2022 |
| Rachman Ilya M | ▲ Buy | Open Market | 2,500 | $13K | 12/20/2021 |
| Hsu Jason | ▼ Sell | Other | 3,915,913 | $3.3M | 12/20/2021 |
| Hsu Jason | ▲ Buy | Open Market | 50,000 | $250K | 12/20/2021 |
| Torchilin Vladimir P | ▲ Buy | Open Market | 3,000 | $15K | 12/20/2021 |
| Morris Gabriel S | ▼ Sell | Other | 74,116 | $63K | 12/20/2021 |
| Morris Gabriel S | ▼ Sell | Other | 123,527 | $105K | 12/20/2021 |
| Morris Gabriel S | ▼ Sell | Other | 123,176 | $105K | 12/20/2021 |
| Morris Gabriel S | ▲ Buy | Open Market | 2,000 | $10K | 12/20/2021 |
| Ng Carey | ▼ Sell | Other | 1,000,221 | $850K | 12/20/2021 |
| Ng Carey | ▲ Buy | Open Market | 25,000 | $125K | 12/20/2021 |
| Torchilin Vladimir P | ▲ Buy | Open Market | 2,200 | $10K | 12/17/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
IMMX Holds Shareholder and Analyst Call
Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.
IMMX Holds Shareholder and Analyst Call. Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.